Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (1594)	3/14/2006 10:41:39 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NGEN Opened with an upgap for 2nd day on a roll.<g> It announced today that it was issued a U.S. Patent for a method of separating biomolecules or cell particles on a chip using electronic current. bigcharts.marketwatch.com biz.yahoo.com NGEN's LTC remains "interesting".<g> bigcharts.marketwatch.com Bernard

To: zeta1961 who wrote (1594)	10/24/2007 2:20:40 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ONCY Is continuing the near term UT that started on Sep 28 from the $1.50 level.<g> bigcharts.marketwatch.com It is going to present a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Frisco. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial Wednesday October 24, 7:00 am ET CALGARY, Oct. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that a poster presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN®/radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The conference runs from October 22-26, 2007. "We are very encouraged with the results of this trial to date," said Dr. Brad Thompson, President and CEO of Oncolytics. "The data is supportive of our ongoing Phase II REOLYSIN /radiation cotherapy trial in the U.K." The interim results of the Ia/Ib trial demonstrate that intratumoural treatment with REOLYSIN and radiation is well tolerated and results in both local and remote anti-tumour activity in patients with a variety of advanced cancers. Oncolytics continues to enroll patients in the Ib portion of this trial, and is also actively enrolling patients in a Phase II trial examining this treatment combination. These interim results were also presented in early October at the NCRI Cancer Conference in Birmingham, U.K. Snip The stock is starting to get oof the DT coming from the March 2006 H at the $5.25 level bigcharts.marketwatch.com The Apr 2004 H at the $9.84 level looks somewhat far at present.<g> bigcharts.marketwatch.com Bernard